Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-upJoost H. van den Berg, John B.A.G. Haanen, Samira Michels et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 196
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trialJessica S.W. Borgers, Marit M. van Buuren, Divya Lenkala et al.|Nature Medicine|2025Cited by 40